Search research articles
Contact Us
Filters
Showing results (871-880 of 886) with videos related to
Page
of 89
Sort By:
Journal of Medicinal Chemistry
|
September 19, 2023
Discovery of <b>12</b> (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders
Wei Meng, Robert Brigance, James Mignone, et al.
Journal of Medicinal Chemistry
|
October 6, 2021
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders
Huji Turdi, Hannguang Chao, Jon J Hangeland, et al.
Annals of Hematology
|
July 8, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML
Lydia Kretschmer, Leo Ruhnke, Christoph Schliemann, et al.
Cancers
|
April 3, 2021
Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis
Rouven Hoefflin, Adriana Lazarou, Maria Elena Hess, et al.
Blood
|
May 1, 2020
Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers
Alexandre Fagnan, Frederik Otzen Bagger, Maria-Riera Piqué-Borràs, et al.
Gut
|
November 23, 2016
Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome
Maria Henström, Lena Diekmann, Ferdinando Bonfiglio, et al.
Journal of Medicinal Chemistry
|
January 24, 2017
Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode
Elizabeth A Jurica, Ximao Wu, Kristin N Williams, et al.
Journal of Medicinal Chemistry
|
January 10, 2018
Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists
Jun Shi, Zhengxiang Gu, Elizabeth Anne Jurica, et al.
Bioorganic & Medicinal Chemistry
|
April 8, 2023
Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities
Elizabeth A Jurica, Ximao Wu, Kristin N Williams, et al.
Circulation
|
October 19, 2022
Mutant Phosphodiesterase 3A Protects From Hypertension-Induced Cardiac Damage
Maria Ercu, Michael B Mücke, Tamara Pallien, et al.
Page
of 89
Search research articles
Search
Showing results (871-880 of 886) with videos related to
Sort By:
Page
of 89
Journal of Medicinal Chemistry
|
September 19, 2023
Discovery of <b>12</b> (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders
Wei Meng, Robert Brigance, James Mignone, et al.
Journal of Medicinal Chemistry
|
October 6, 2021
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders
Huji Turdi, Hannguang Chao, Jon J Hangeland, et al.
Annals of Hematology
|
July 8, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML
Lydia Kretschmer, Leo Ruhnke, Christoph Schliemann, et al.
Cancers
|
April 3, 2021
Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis
Rouven Hoefflin, Adriana Lazarou, Maria Elena Hess, et al.
Blood
|
May 1, 2020
Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers
Alexandre Fagnan, Frederik Otzen Bagger, Maria-Riera Piqué-Borràs, et al.
Gut
|
November 23, 2016
Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome
Maria Henström, Lena Diekmann, Ferdinando Bonfiglio, et al.
Journal of Medicinal Chemistry
|
January 24, 2017
Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode
Elizabeth A Jurica, Ximao Wu, Kristin N Williams, et al.
Journal of Medicinal Chemistry
|
January 10, 2018
Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists
Jun Shi, Zhengxiang Gu, Elizabeth Anne Jurica, et al.
Bioorganic & Medicinal Chemistry
|
April 8, 2023
Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities
Elizabeth A Jurica, Ximao Wu, Kristin N Williams, et al.
Circulation
|
October 19, 2022
Mutant Phosphodiesterase 3A Protects From Hypertension-Induced Cardiac Damage
Maria Ercu, Michael B Mücke, Tamara Pallien, et al.
Page
of 89